Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Trelegy

Sanofi reception

Dupixent helps put Sanofi back on growth track

French drugs giant sees an 8% rise in vaccine sales

AstraZeneca AZ

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Clinical data from the TSLP targeting antibody is due in 2020

AstraZeneca AZ

PMCPA takes AZ to task over asthma drug press release

Concluded that the data in the release had not been “placed in context”

- PMLiVE

GSK gets maintenance indication for Trelegy

Will now treat airflow obstruction in COPD patients

AstraZeneca AZ

AZ’s COPD triple data sets up market clash with GSK

KRONOS trial showed significant improvements in lung function tests over two-drug combos

- PMLiVE

EMA approves GSK’s triple COPD therapy

Trelegy can now be marketed as a maintenance treatment in Europe

AstraZeneca AZ

AZ prices severe asthma drug Fasenra below competition

The discounted drug will cost $38,000 in the first year

AstraZeneca AZ

AZ severe asthma drug benralizumab backed by CHMP

The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma

- PMLiVE

Asthma: beyond the blue and the brown

Innovation in respiratory medicine

AstraZeneca AZ

Setback for AZ as tralokinumab flunks asthma trial

Puts more pressure on AZ’s benralizumab to reach its potential

- PMLiVE

With US approval, GSK now needs rapid uptake for COPD triple

Aims to quickly launch the predicted blockbuster to revive its R&D portfolio

- PMLiVE

GSK preps COPD filing for asthma pioneer Nucala

Moves despite reporting mixed data for the treatment earlier this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links